Patents by Inventor Kevin D. Kreutter

Kevin D. Kreutter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11897900
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: February 13, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Patent number: 11827638
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: November 28, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Genesis M. Bacani, Wenying Chai, Tatiana Koudriakova, Paul J. Krawczuk, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Mark Seierstad, Russell C. Smith, Mark S. Tichenor, Jennifer D. Venable, Aihua Wang
  • Publication number: 20230150985
    Abstract: Chromanone compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the inhibition of antigen presentation by HLA-DR.
    Type: Application
    Filed: March 30, 2021
    Publication date: May 18, 2023
    Inventors: Joseph Kent Barbay, Stephane Becart, Kelly L. Damm-Ganamet, Gavin C. Hirst, Kevin D. Kreutter, Alec D. Lebsack
  • Publication number: 20230097422
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Application
    Filed: March 25, 2022
    Publication date: March 30, 2023
    Inventors: Nidhi ARORA, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J.M. Wiener
  • Publication number: 20230077316
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CPTS1, and the treatment of CPTS1-mediated disorders.
    Type: Application
    Filed: October 22, 2021
    Publication date: March 9, 2023
    Inventors: Kevin D. KREUTTER, Lewis Whitehead, Angela V. West, Steven K. Albanese, Andreas Verras, Shaughnessy Robinson, Neelu Kaila, Sebastien Campos, Kevin Demarco
  • Publication number: 20220315604
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: December 18, 2020
    Publication date: October 6, 2022
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Publication number: 20220315557
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.
    Type: Application
    Filed: November 25, 2020
    Publication date: October 6, 2022
    Inventors: Tianbao LU, Brett Douglas Allison, Joseph Kent Barbay, Peter J. Connolly, Maxwell David Cummings, Gaston Diels, James Patrick Edwards, Kevin D. Kreutter, Ulrike Philippar, Fang Shen, Johannes Wilhelmus John Fitzgerald Thuring, Tongfei Wu, Didier Jean-Claude Berthelot
  • Patent number: 11427601
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: August 30, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Patent number: 11319329
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: May 3, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener
  • Patent number: 11254673
    Abstract: The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: February 22, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Kent Barbay, Wenying Chai, Wendy Eccles, Michael D. Hack, Aaron T. Herrmann, William M. Jones, Paul J. Krawczuk, Kevin D. Kreutter, Alec D. Lebsack, Daniel J. Pippel, Alexander R. Rovira, Ronald L. Wolin
  • Publication number: 20210340143
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Application
    Filed: June 23, 2021
    Publication date: November 4, 2021
    Inventors: Tatiana Koudriakova, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Russell C. Smith, Mark S. Tichenor, Aihua Wang
  • Publication number: 20210300918
    Abstract: The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
    Type: Application
    Filed: May 29, 2020
    Publication date: September 30, 2021
    Inventors: J. Kent Barbay, Wenying Chai, Wendy Eccles, Michael D. Hack, Aaron T. Herrmann, William M. Jones, Paul J. Krawczuk, Kevin D. Kreutter, Alec D. Lebsack, Daniel J. Pippel, Alexander R. Rovira, Ronald L. Wolin
  • Patent number: 11059823
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tatiana Koudriakova, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Russell C. Smith, Mark S. Tichenor, Aihua Wang
  • Publication number: 20210206768
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Application
    Filed: March 16, 2021
    Publication date: July 8, 2021
    Inventors: Genesis M. Bacani, Wenying Chai, Tatiana Koudriakova, Paul J. Krawczuk, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Mark Seierstad, Russell C. Smith, Mark S. Tichenor, Jennifer D. Venable, Aihua Wang
  • Patent number: 11040031
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: June 22, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tianbao Lu, Peter J. Connolly, Maxwell David Cummings, Joseph Kent Barbay, Kevin D. Kreutter, Tongfei Wu, Gaston Stanislas Marcella Diels, Jan Willem Thuring, Ulrike Philippar, James Patrick Edwards, Fang Shen
  • Patent number: 10981911
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: April 20, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Genesis M. Bacani, Wenying Chai, Tatiana Koudriakova, Paul J. Krawczuk, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Mark Seierstad, Russell C. Smith, Mark S. Tichenor, Jennifer D. Venable, Aihua Wang
  • Publication number: 20210101910
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Application
    Filed: May 13, 2020
    Publication date: April 8, 2021
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J.M. Wiener
  • Patent number: 10954214
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 23, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tianbao Lu, Brett Douglas Allison, Joseph Kent Barbay, Peter J. Connolly, Maxwell David Cummings, Gaston Diels, James Patrick Edwards, Kevin D. Kreutter, Ulrike Philippar, Fang Shen, Johannes Wilhelmus John Fitzgerald Thuring, Tongfei Wu, Didier Jean-Claude Berthelot
  • Patent number: 10947252
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: March 16, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Patent number: 10934310
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: March 2, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener, Yao Wu, Kun Xiao, Feihuang Zhang, Yaoping Zhu